SEC Form 4 · accession 0001193125-26-265335
Metagenomi Therapeutics, Inc. · MGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pamela Wapnick
Officer — Chief Financial Officer
Period of report
Jun 5, 2026
Accepted (ET)
Jun 10, 2026 · 11:23 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001785279
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 5, 2026 | S | 2,884 | $1.299 | D | 208,491 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person.